SKBI

In terms of total return performance, the HSBC/Nasdaq SKBI Total Return Index, which tracks the return of an emerging Sukuk portfolio consisting of 46 USD/GBP/JPY/EUR- denominated fixed/floating rate vanilla issuances, returned 9.69 per cent during 2012, up from 7.13 per cent in 2011.

Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary healthcare and medical care products, announced on Monday the appointment of Bing Mei as its permanent chief financial officer, effective 29 July 2011.